{
    "clinical_study": {
        "@rank": "93958", 
        "acronym": "SIGNIFY", 
        "arm_group": [
            {
                "arm_group_label": "TP53 mutation carriers", 
                "description": "Carriers of TP53 mutation not known to be low penetrance"
            }, 
            {
                "arm_group_label": "Population controls", 
                "description": "Population controls will be sex and aged matched (+/- 5 years) to the TP53 mutation carrier group, with no personal history of cancer and no family history of cancer diagnosed under 50 years"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is aimed at exploring the use of whole body MRI for early cancer detection in\n      TP53 mutation carriers and population controls, with the hypothesis that more cancers will\n      be detected in the TP53 mutation carrier group. A secondary end-point will be the number of\n      incidental findings detected and subsequent investigations required. A series of\n      questionnaires will be used to assess the psychological impact of screening on both the\n      study and control group."
        }, 
        "brief_title": "Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome", 
        "condition": "Li-Fraumeni Syndrome", 
        "condition_browse": {
            "mesh_term": "Li-Fraumeni Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Carrier of germline TP53 mutation which, in the view of the geneticist, is not known\n             to be low penetrance OR non-related individual with no personal history of malignancy\n             and no first degree relatives diagnosed with malignancy under the age of 50 years\n\n          -  Age between 18 and 60\n\n          -  Able to give informed consent\n\n        Exclusion Criteria:\n\n          -  Individual with low penetrance TP53 mutation\n\n          -  Individual with TP53 variant of unknown significance.\n\n          -  Previous malignancy diagnosed < 5 years ago in TP53 carriers (except non-melanomatous\n             skin cancer or cervical CIS) Previous history of malignancy in non-related controls\n             (except non-melanomatous skin cancer or cervical CIS)\n\n          -  Current symptoms suggestive of malignancy\n\n          -  Contraindication to MRI (such as non-MR compatible metal implants) as specified by\n             the standard MR safety checklist\n\n          -  Claustrophobia\n\n          -  ECOG performance status >2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The TP53 mutation carriers will be recruited from genetics clinics and through\n        advertising.\n\n        The population controls will be recruited through advertising"
            }
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737255", 
            "org_study_id": "CCR3802"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "TP53 mutation carriers", 
                    "Population controls"
                ], 
                "description": "Individuals will undergo whole body and brain MRI", 
                "intervention_name": "Whole body MRI", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "TP53 mutation carriers", 
                    "Population controls"
                ], 
                "description": "All recruits will complete questionnaires at 6 time points to assess psychological impact", 
                "intervention_name": "Psychological questionnaires", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Li-Fraumeni Syndrome", 
            "Whole Body Magnetic Resonance Imaging", 
            "TP53", 
            "Psychological Impact"
        ], 
        "lastchanged_date": "November 27, 2012", 
        "location": {
            "contact": {
                "email": "rosalind.eeles@icr.ac.uk", 
                "last_name": "Rosalind A Eeles, FRCP FRCR", 
                "phone": "44 208 661 3642"
            }, 
            "contact_backup": {
                "email": "elizabeth.bancroft@icr.ac.uk", 
                "last_name": "Elizabeth K Bancroft, RGN MMedSci", 
                "phone": "44 207 808 2136"
            }, 
            "facility": {
                "address": {
                    "city": "Sutton", 
                    "country": "United Kingdom", 
                    "state": "Surrey", 
                    "zip": "SM2 5PT"
                }, 
                "name": "Cancer Genetics Unit, Royal Marsden Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "2", 
        "official_title": "Magnetic Resonance Imaging Screening In Li Fraumeni Syndrome: An Exploratory Whole Body MRI Study", 
        "overall_contact": {
            "email": "rosalind.eeles@icr.ac.uk", 
            "last_name": "Rosalind Eeles, PhD", 
            "phone": "44 208 661 3642"
        }, 
        "overall_contact_backup": {
            "email": "emma.killick@icr.ac.uk", 
            "last_name": "Emma Killick, MBBS", 
            "phone": "44 208 661 3375"
        }, 
        "overall_official": {
            "affiliation": "Institute of Cancer Research, Surrey, UK", 
            "last_name": "Rosalind Eeles, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: NHS Health Research Authority"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Following MRI scan further investigations may be required to diagnose malignancy", 
            "measure": "Diagnosis of malignant disease", 
            "safety_issue": "No", 
            "time_frame": "Within 12 months of MRI scan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737255"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Further investigations may be required following the MRI to characterise such findings.", 
                "measure": "Diagnosis of relevant non-malignant disease", 
                "safety_issue": "No", 
                "time_frame": "12 months following MRI scan"
            }, 
            {
                "measure": "Diagnosis of non-relevant disease, number and type of investigations required", 
                "safety_issue": "No", 
                "time_frame": "12 months following MRI"
            }, 
            {
                "description": "Psychological questionnaires to be completed at intervals up till 12 months post scan", 
                "measure": "Psychological impact of MRI screening", 
                "safety_issue": "No", 
                "time_frame": "12 months following MRI screening"
            }
        ], 
        "source": "Institute of Cancer Research, United Kingdom", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Cancer Research UK", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Institute for Health Research, United Kingdom", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Institute of Cancer Research, United Kingdom", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2012"
    }
}